Abstract: Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for treating estrogen receptor-positive breast cancer.

Abstract: Disclosed are a pyrrolopyrazole spiro compound, and the use thereof in preparing a drug for treating related diseases. The present invention specifically relates to a compound as represented by formula (I?), and a stereoisomer and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.

Abstract: The present disclosure discloses a faucet device with a self-cleaning function, comprising: a faucet mechanism, a control mechanism, a self-cleaning mechanism, and a beverage inlet passage. The beverage inlet passage is configured to be in communication with a beverage source, the faucet mechanism comprises a first passage configured to be in communication with a water source and a second passage configured to be in communication with a beverage source, and the control mechanism is connected to an inlet of the second passage, the beverage inlet passage, and the self-cleaning mechanism to control the beverage inlet passage to supply a beverage supplied by the beverage source to the second passage or to enable the second passage to be cleaned by the self-cleaning mechanism.

Abstract: Provided are a salt form of an estrogen receptor down-regulator, a crystalline form thereof, and a preparation method therefor

Abstract: The present disclosure provides a salt form and a crystal form of a sulfonylurea ring substituted compound and a specific crystal form A thereof, and also provides an application thereof in preparation of medicaments for treating bacterial infection-related diseases. The crystal form A of the compound is easy to obtain and has good physical stability and chemical stability, with high industrial application value and economic value. The compound of the present disclosure has good water solubility, suitable for intravenous administration, and excellent in pharmacokinetic properties; has good safety; has good efficacy, and will be used for treatment of bacterial infection-related diseases.

Abstract: A kitchen faucet with a garbage disposer includes a faucet unit, the garbage disposer, and a sensing unit. The faucet unit includes a water outlet passage unit, and the water outlet passage unit is disposed with a first control valve configured to control an opening and a closing of the water outlet passage unit. The garbage disposer is located under a water outlet of the water outlet passage unit of the faucet unit. The sensing unit is disposed on the faucet unit and is configured to generate a normal water outlet instruction and a garbage disposal instruction respectively according to a long sensing distance and a short sensing distance. The first control valve is configured to be opened and closed through the normal water outlet instruction, and the first control valve and the garbage disposer are respectively configured to be opened and closed through the garbage disposal instruction.

Abstract: A pyrrole-substituted indolone derivative or pharmaceutically acceptable salts thereof, and a preparation method therefor and application thereof. The pyrrole-substituted indolone derivative or pharmaceutically acceptable salts thereof is simple to synthesize, easy to prepare, rich in raw materials for synthesis, and has an inhibitory effect on a plurality of tyrosine kinases, especially has higher selective inhibitory activity against KDR (VEGFR2), and FLT3 and its mutants, and can avoid toxic side effects caused by inhibiting KDR.

Abstract: Disclosed is an aminopyrimidine compound as a CDK2/4/6 inhibitor, and specifically disclosed are the compound represented by formula (I) and a pharmaceutically acceptable salt thereof, and an application of the compound represented by formula (I) and the pharmaceutically acceptable salt thereof in the preparation of a medicament for treating solid tumor.

Abstract: An indoline compound. Specifically disclosed is an application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in the preparation of drugs for treating related diseases.

Abstract: The present application discloses a class of guaianolide sesquiterpene lactone derivatives and pharmaceutical use thereof. The guaianolide sesquiterpene lactone derivative or a pharmaceutically acceptable salt thereof is shown as general formula I. In the present application, a class of novel guaianolide sesquiterpene lactone derivatives are found by structural optimization with abundant natural ingredients such as parthenolide and dehydrocostus lactone as raw materials, which derivatives have good inhibitory activity on the activation of the NLRP3 inflammasome, and the chemical stability, water solubility and oral bioavailability of which are significantly improved, and it is verified by experiments that the derivatives have inhibitory effects on the activity of the NLRP3 inflammasome and have potential pharmaceutical applications.

Abstract: A salt form of a tetra-substituted olefin compound, a crystal of the compound and the salt, and a preparation method relating to a crystal of a compound represented by formula (I), a salt thereof, a crystal of the salt thereof, and a preparation method therefor.

Abstract: Disclosed are a salt form used as a CDC7 inhibitor and a crystal form thereof, and specifically disclosed is a compound represented by formula (II), a crystal form thereof, a preparation method thereof, and an application thereof in the preparation of a drug for preventing or treating tumors.

Abstract: A synthesis method of alpha-hydroxycarboxylic acid ester is provided. In the method, an alpha-hydroxycarboxylic acid and an alcohol are taken as raw materials, one or more of boric acid, metaboric acid, pyroboric acid, and boric anhydride is taken as a catalyst, and one of cyclohexane, toluene, benzene, and alcohols is taken as a water-carrying agent. A reaction temperature is kept in range of 100-160° C., produced water is separated by an oil-water separator, and the alpha-hydroxycarboxylic acid ester is synthesized directly. After an esterification reaction, the water-carrying agent and unreacted alcohol are distilled by vacuum fractionation to obtain a crude product, and refined alpha-hydroxycarboxylic acid ester is obtained by performing neutralization, water washing, and vacuum rectification on the crude product. The alpha-hydroxycarboxylic acid ester prepared by the method has high purity and light color, and can be used as green solvent, surfactant, chiral resolution agent and plasticizer.

Abstract: Disclosed is a type of indolo heptamyl oxime analog crystalline form as a PARP inhibitor and a method for preparing the same, specifically relating to a crystalline form of a compound of formula (I) and a method for preparing the same.

Abstract: An embodiment of the present disclosure provides a water outlet device including a first water outlet fixedly mounted on a worktable, a second water outlet detachably connected with the first water outlet or the worktable for an operator to hold, and a control unit for being mounted on the worktable and including a controller and a power source. The power source is electrically connected with the controller for supplying power for the controller. The controller is configured to control opening or closing of the first water outlet and/or the second water outlet.

Abstract: A pyrimidine ring compound represented by formula (III), or a pharmaceutically acceptable salt thereof, and an application thereof in preparation of a medication for treating related diseases.

Abstract: Disclosed is a class of compounds containing arylsultam, and specifically disclosed are a compound represented by formula (II), and a pharmaceutically acceptable salt or an isomer thereof.

Abstract: Disclosed in the present invention is a novel compound as FLT3 and AXL inhibitors. Specifically, disclosed are a compound represented by formula (I) and a pharmacologically acceptable salt thereof.

Abstract: Disclosed is a class of compounds containing arylsultam, and specifically disclosed are a compound represented by formula (II), and a pharmaceutically acceptable salt or an isomer thereof.